Nuvama raises target price for Ultratech. 3 reasons why…

The brokerage firm, Nuvama, has raised its target price for UltraTech Cement to Rs 11,574 per share while maintaining its ‘HOLD’ rating on the stock. According to them, UltraTech Cement has delivered a strong performance in Q3FY25 and exceeded expectations in several key areas.

However, the firm is worried on the valuation front. They maintained the Hold rating, as they believe the stock’s current valuation suggests a more cautious approach.

Nuvama raised target price on UltraTech Cement

The brokerage firm has raised UltraTech Cement’s target price to Rs 11,57 from Rs 11,238 based on an 18x EV/EBITDA multiple for Q3FY27E.

“We are marginally revising up FY25E, FY26E, and FY27E EBITDA by 1% each,” indicating a growth in UltraTech’s future performance but also pointed caution at the current stock price levels.

UltraTech Cement reported an 11% YoY consolidated volume growth in Q3FY25, which surpasses the industry’s growth of approximately 5%. The company’s EBITDA exceeded Nuvama’s estimate by around 8%. The brokerage firm added, “UltraTech’s ability to consistently outperform the industry demonstrates its competitive advantage and robust market share.”

UltraTech management optimistic about growth

Furthermore, the brokerage in its report added that UltraTech Cement’s management is optimistic about growth. The company expects its domestic capacity to reach approximately 183 million tons by the end of FY25, with a further rise to 209 MT by FY27.

Cement realisations improve

Cement realisation saw a 2.5% quarter-on-quarter (QoQ) improvement. “Realisation improved by 2.5% QoQ, with current prices in central and western regions around 1.5% higher than the Q3FY25 average,” added the brokerage.

According to the firm, “The ongoing capacity expansion, including the integration of Kesoram and India Cements, positions UltraTech for continued leadership in the Indian cement market.”

Also ReadPaytm shares slide 9% on alleged ED investigation on crypto scam UltraTech Cement Q3 performance

UltraTech Cement, part of the Aditya Birla Group, reported a profit of Rs 1,473.51 crore for the third quarter of the fiscal year, a 16.98% decline compared to Rs 1,774.78 crore in the same period last year. Despite the drop in profit, the company exceeded expectations. Revenue from operations rose by 2.71%, reaching Rs 17,193.33 crore, up from Rs 16,739.97 crore in the third quarter of FY24. Additionally,

 » Read More

Related Articles

Will DA calculation formula be changed for central govt employees? Here’s what new proposal says

DA Calculation for Central Government Employees: The Confederation of Central Government Employees and Workers has urged the Centre to consider revising the computation formula for dearness allowance for central staff and pensioners. In a letter addressed to the Union cabinet secretary, S B Yadav, secretary general of the confederation – representing about 7 lakh employees

SC stays HC ruling granting tax treaty benefits to Tiger Global

The Supreme Court (SC) on Friday stayed a 2024-Delhi High Court (HC) ruling, which had allowed a private equity firm Tiger Global to avail tax benefits arising from the India-Mauritius Double Taxation Avoidance Agreement (DTAA), on transactions made prior to April 1, 2017. Experts say the SC stay order may bring tax-related uncertainty for foreign

JSW Steel Q3 Results: Profit plummets 70.65% to Rs 719 crore, beats estimates

JSW Steel Ltd on Friday reported a profit of Rs 719 crore during the fiscal third quarter, posting a decline of 70.65 per cent from Rs 2450 crore recorded during the corresponding quarter of FY24, surpassing estimates. It posted revenue from operations at Rs 41,378 crore, down 1.34 per cent as against Rs 41,940 crore

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Will DA calculation formula be changed for central govt employees? Here’s what new proposal says

DA Calculation for Central Government Employees: The Confederation of Central Government Employees and Workers has urged the Centre to consider revising the computation formula for dearness allowance for central staff and pensioners. In a letter addressed to the Union cabinet secretary, S B Yadav, secretary general of the confederation – representing about 7 lakh employees

SC stays HC ruling granting tax treaty benefits to Tiger Global

The Supreme Court (SC) on Friday stayed a 2024-Delhi High Court (HC) ruling, which had allowed a private equity firm Tiger Global to avail tax benefits arising from the India-Mauritius Double Taxation Avoidance Agreement (DTAA), on transactions made prior to April 1, 2017. Experts say the SC stay order may bring tax-related uncertainty for foreign

JSW Steel Q3 Results: Profit plummets 70.65% to Rs 719 crore, beats estimates

JSW Steel Ltd on Friday reported a profit of Rs 719 crore during the fiscal third quarter, posting a decline of 70.65 per cent from Rs 2450 crore recorded during the corresponding quarter of FY24, surpassing estimates. It posted revenue from operations at Rs 41,378 crore, down 1.34 per cent as against Rs 41,940 crore

What is HPZ Token scam that has Paytm, Razorpay, PayU, other payment gateways in ED spotlight

The HPZ Token scam, in which eight payment gateways, including Paytm, PayU, and Razorpay, have been under the Enforcement Directorate’s (ED) scanner as per a report by The Times of India, is said to have started with the launch of the ‘HPZ Token’ mobile app. The app-based token promised investors humongous gains by investing in

Pharma Index falls sharply. The biggest losers are…

Most pharma stocks traded in the red during Friday’s session, with the Nifty Pharma index falling 2.19% at 21,854.15. Dr. Reddy’s Laboratories led the decline, shedding over 5.20%, followed by Mankind Pharma, which also posted significant losses. Amongst the major losers in the Nifty Pharma stocks, Dr. Reddy’s Laboratories saw the steepest decline, dropping 5.15%